Diagnosis and Management of Monoclonal Gammopathy and Smoldering Multiple Myeloma
- PMID: 33347744
- DOI: 10.6004/jnccn.2020.7660
Diagnosis and Management of Monoclonal Gammopathy and Smoldering Multiple Myeloma
Abstract
The presence of monoclonal proteins is common, with a prevalence in the United States around 5% that increases with age. Although most patients are asymptomatic, most cases are caused by a clonal plasma cell disorder. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) are asymptomatic precursor conditions with variable risk of progression to multiple myeloma. In recent years, significant progress has been made to better understand the factors that lead to the development of symptoms and progression to myeloma. This review summarizes the current diagnosis treatment guidelines for MGUS and SMM and highlights recent advances that underscore a shifting paradigm in the evaluation and management of plasma cell precursor conditions.
Copyright © 2020 by the National Comprehensive Cancer Network.
Similar articles
-
SOHO State of the Art Updates and Next Questions: Diagnosis and Management of Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma.Clin Lymphoma Myeloma Leuk. 2024 Oct;24(10):653-664. doi: 10.1016/j.clml.2024.03.008. Epub 2024 Mar 16. Clin Lymphoma Myeloma Leuk. 2024. PMID: 38641486 Review.
-
Monoclonal gammopathies of unknown significance and smoldering myeloma: Assessment and management of the elderly patients.Eur J Intern Med. 2018 Dec;58:57-63. doi: 10.1016/j.ejim.2018.05.029. Epub 2018 Jun 12. Eur J Intern Med. 2018. PMID: 29907380 Review.
-
Smoldering multiple myeloma 40 years later: a story of unintended disease.Expert Rev Hematol. 2021 Feb;14(2):149-153. doi: 10.1080/17474086.2021.1875815. Epub 2021 Jan 21. Expert Rev Hematol. 2021. PMID: 33430658 Review.
-
Smoldering multiple myeloma current treatment algorithms.Blood Cancer J. 2022 Sep 5;12(9):129. doi: 10.1038/s41408-022-00719-0. Blood Cancer J. 2022. PMID: 36064707 Free PMC article. Review.
-
[Expert consensus on the comprehensive management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma in China (2025)].Zhonghua Xue Ye Xue Za Zhi. 2025 Mar 14;46(3):198-208. doi: 10.3760/cma.j.cn121090-20241122-00469. Zhonghua Xue Ye Xue Za Zhi. 2025. PMID: 40355349 Free PMC article. Chinese.
Cited by
-
An eye-catching atypical illustration of the evaluation and management of AL amyloidosis secondary to myeloma.Clin Case Rep. 2021 Dec 9;9(12):e05176. doi: 10.1002/ccr3.5176. eCollection 2021 Dec. Clin Case Rep. 2021. PMID: 34938552 Free PMC article.
-
EHA-EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma.Nat Rev Clin Oncol. 2025 Jul 7. doi: 10.1038/s41571-025-01041-x. Online ahead of print. Nat Rev Clin Oncol. 2025. PMID: 40624367 Review.
-
Efficacy and Safety of Anti-CD38 Monoclonal Antibodies in Patients with Relapsed or Refractory Multiple Myeloma: A Meta-Analysis of Randomized Clinical Trials.J Pers Med. 2024 Mar 29;14(4):360. doi: 10.3390/jpm14040360. J Pers Med. 2024. PMID: 38672988 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical